​​

​​

SunRx is a health care technology company that assists healthcare facilities with 340B administration, including split-billing and 340B contract pharmacy network administration and other pharmacy transactions to Eligible Patients; and other technology products which assist healthcare facilities to optimize their supply chain and pharmacy operations.
​​


​Blog Posts​

​​
feature_pillsHighCost.jpg
What's So Special About Specialty Pharmacy?

Specialty pharmacy can be defined in many ways. Really, they are all correct as there is not one single source of truth for the definition. Specialty pharmacies do certain services for those patients that are chronically ill, covering a wide range of disease states and the costs of these medications can vary greatly. However, not all specialty pharmacies operate in the same way. Some specialty pharmacies can support all the disease states and service all 50 of the United States, while others might be more disease state focused or with just a regional ability to dispense. The differences in specialty pharmacies, the disease states they serve, and the associated definitions take on many shapes and sizes and is perhaps the reason it is so difficult to agree on one definition.

One thing that everyone seems to agree on is that specialty pharmacy is growing! The continued development of therapies for the chronic disease states has led to much of the growth in the specialty pharmacy segments. These new drugs often require a higher tracking of patient clinical data, side effects and outcomes, all of which fall into the services that specialty pharmacies are designed to support.




​​ Duplicate Discounts Under 340B Program

There are not that many core requirements within the 340B Statute. For being on its face, what appears a fairly "simple" program, it is instead turning into a mighty complicated program. One of two main requirements is "no duplicate discounts."

A "duplicate discount" is when a prescription (or administration) of a 340B priced outpatient drug is also subject to a pharmaceutical manufacturer's rebate under a Medicaid program. Purchasing a drug at a discount under 340B and the claim also being subject to a rebate under a state Medicaid program would subject the manufacturer to "two" (duplicate) discounts. Filling a prescription and billing a managed Medicaid plan is allowed so long as the state is aware, so they withhold that prescription from their rebate submission to the manufacturer. The opinion of manufacturers these days is that there are "rampant" duplicate discounts being paid out.



Picture1.png






​​ Protect Your 340B Covered Entity from Risk

The Indiana Hospital Association and SUNRx understand the importance of the 340B Drug Pricing Program and the value it brings to you. SUNRx has been a trusted TPA since 2006 and they’re here to help. SUNRx has had a partnership with Indiana Hospital Association and over 30 hospital associations across the country.  

SUNRx maintains a vital security infrastructure, monitors security events, timely remediates security issues, and performs quarterly vulnerability scans and security posture analysis. They also maintain annual SSAE-18 SOC1 and SOC2 audits, which are performed by BDO. 

Let SUNRx help you understand and simplify 340B! Please contact John Bretz​ for more information. 


​​ Optimize Your 340B Program and Stay Compliant

More than ever, it is essential to work with a 340B TPA who can support your entity regarding pharmacy expansion. Hospitals and FQHCs should regularly monitor their 340B program and evaluate for expansion opportunities to ensure their programs remain optimized and compliant.  

We want you to know that SUNRx provides covered entity clients with: 

  • Seamless access to Walmart, Kroger, Rite Aid, as well as many other large, regional, and independent pharmacies
  • Annual SOC-1 and SOC2 audits conducted by third-party auditor, BDO. 

Of note, SUNRx services do not include charging a pharmacy minimum or switch fees.

In today’s world, it is increasingly important to work with a 340B TPA with a strong track record, great relationships with pharmacies and strong security infrastructure to protect clients and their data.

Please contact John Bretz​ for more information. ​​​



A 340B Discount Card Program Can Lessen the Healthcare Burden on the Uninsured

Hospitals and community health centers, including FQHCs (all, 340B Covered Entities) participating in 340B are not-for-profit and are required to provide a community benefit. The mission of ​​Covered Entities (CEs) participating in the 340B program is to provide healthcare services to everyone regardless of ability to pay. In most cases, local government agencies have contracted with these CEs to care for low-income individuals who are not entitled to benefits under Medicare or Medicaid.

All 340B eligible hospitals and clinics (CEs) are burdened by the cost to provide healthcare to patients, without regard to their ability to pay for those services, and struggle to stretch these scarce resources when providing crucial services to their patients in their communities. Low-income patients that seek healthcare from these CEs usually can’t afford to pay the high cost of prescription medications and therefore run the risk of re-admissions to these entities due to lack of prescription adherence. These patients often frequent the emergency rooms of hospitals or have increased visits to the clinics because their health issues are not under control. This leads to increased healthcare costs and longer wait times for all patients. 

Implementing and executing an effective program to provide access to affordable prescription medications is a foundational element to effective population health.

View the full blog: https://www.sunrx.com/resources/blog/340b-discount-card-program-can-lessen-healthcare-burden-uninsured


​Additional Resources

SUNRx 340B Solutions for Hospitals.pdf

SUNRx Advanced Claims Capture.pdf

SUNRx Contract Pharmacy.pdf

SUNRx Overview 340B Solutions.pdf

SUNRx Uninsured 340B Prescription Discount Card.pdf



​​​​​​​


SERVICES ENDORSED by IHA:

Complete 340B drug program management

C​​ONTACT:

John Bretz
Director of Strategic Relations
(267) 800-5390​